



MDHHS – MCiR Release Notes

Version 2022 – MCiR OLTP 2022 9.3.0.9.5.2–RFC 208348

Release Date: October 8, 2022

MCiR Assessment & Forecasting

Forecast and evaluate dose of PCV15 or PCV13 as dose for children (Ref #1590)

On June 22, 2022, the Advisory Committee on Immunization Practices recommended use of PCV15 as an option for pneumococcal conjugate vaccination of persons aged <19 years, according to currently recommended PCV13 dosing and schedules. Risk-based recommendations on use of PPSV23 have not changed.

MCiR accepts doses of PCV15 or PCV13 as dose for children using currently recommended dosing schedules

PCV15 was licensed for 6 weeks and older on June 17, 2022

Case example

17355826093

PCV13 (Pevnar13)	1	2 Months	08/01/2021
PCV13 (Pevnar13)	2	4 Months	10/01/2021
PCV15 (VAXNEUVANCE)	3	1 Year 2 Months	08/01/2022
Pneumococcal PCV13/PCV15	Series Complete		

17404148942

PCV13 (Pevnar13)	1	2 Months	03/01/2018		
PCV13 (Pevnar13)	2	4 Months	05/01/2018		
PCV13 (Pevnar13)	3	7 Months	08/01/2018		
Pneumococcal PCV13	YES	4	01/01/2019	01/01/2019	04/01/2019

Gave PCV15 dose after 12 months of age

PCV15 (VAXNEUVANCE)	4	4 Years 9 Months	10/01/2022
Pneumococcal PCV13/PCV15	Series Complete		

MMWR Recommendation 9/16/22

https://www.cdc.gov/mmwr/volumes/71/wr/mm7137a3.htm?s_cid=mm7137a3_w

Doses of PCV15 (CVX 215) given to under 19 years old are not appearing on MCIR screen or reports (Ref #1646)

MCIR now accepts and displays administered PCV15 doses.

Case example

17355826093

PCV15 (VAXNEUVANCE) 3 1 Year 2 Months 08/01/2022

Pneumococcal PCV13/PCV15 Series Complete

17229937342 (72-year-old) pneumococcal adult series forecasts "PCV15/PCV20"

Bug Fixes

Dose given 2 months after last dose of primary series/booster is valid interval to bivalent booster and should not have a Y button. (Ref #1608)

After release of bivalent COVID-19 boosters for adults on October 1, 2022, we received one report of a Y button (does not meet minimum interval) on dose 5. Status did display as Up to Date.

This was corrected October 5, 2022, since doses given 2 months after last dose of primary series or last booster dose is a valid interval to the bivalent booster.

Case example:

16866860829

COVID-19 (PFR 30 mcg)	1	17 Years 8 Months	01/01/2021
COVID-19 (PFR 30 mcg)	2	17 Years 8 Months	01/18/2021
COVID-19 (PFR 30 mcg)	3	18 Years 1 Month	06/30/2021
COVID-19 (PFR-BNT 30mcg/0.3mL)	4	19 Years 2 Months	07/01/2022
COVID-19 (MOD Bivalent Booster 50mcg/0.5mL)	5	19 Years 4 Months	09/08/2022

(No Y button now on dose 5)

Pfizer/Moderna Bivalent Booster Up-to-date

QBP Assessment Failing Due to Exception (Ref #1644)

Upon sending a QBP message, providers were receiving an error on some messages that said "Assessment results are not available. Age may be out of range." 4.5k unique patients were affected.

This was corrected October 8, 2022 by correcting messaging on COVID vaccines.

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at MDHHS-MCIRHelp@michigan.gov.